Unique ID issued by UMIN | UMIN000030883 |
---|---|
Receipt number | R000035260 |
Scientific Title | Photodynamic Therapy (PDT) for malignant brain tumor in children. |
Date of disclosure of the study information | 2018/01/28 |
Last modified on | 2018/01/18 20:54:24 |
Photodynamic Therapy (PDT) for malignant brain tumor in children.
Photodynamic Therapy (PDT) for malignant brain tumor in children.
Photodynamic Therapy (PDT) for malignant brain tumor in children.
Photodynamic Therapy (PDT) for malignant brain tumor in children.
Japan |
Malignant brain tumor in children
Neurosurgery |
Malignancy
YES
Establishment of safety and adequate dose of Talaporfin sodium (Leserphyrin) as photosensitizer in cases of pediatric malignant brain tumor.
Safety,Efficacy
Phase I,II
1. Safety (including photosensitivity test)(phase I)
2. Overall survival (OS) rate at 12 months after PDT (phase II)
1. Overall survival (OS)
2. Progression-free survival (PFS) rate at 6 months after PDT.
3. Progression-free survival
4. Safety (including photosensitivity test)
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine | Device,equipment |
Medication: Talaporfin sodium (Leserphyrin)
Dose: Dose-up from 10mg/square-20mg/square-40mg/square in sequence in every 3 cases since initial enrolled case. Finally, single drip intra-venous infusion of 40mg/square is required.
Timing: 22-26 hours bafore surgical removal.
Laser irradiation in a wave length of 664+/-2nm for tumor removal cavity 22-26 hours after drip intra-venous infusion of Talaporfin sodium.
6 | years-old | <= |
20 | years-old | > |
Male and Female
1. Patients treated at the department of neurosurgery, Tokyo Women's Medical University, Tokyo, Japan(in both outpatient clinic and admission).
2. Man and woman, over the age of 6 years old and below the age of 20 years old at enrollment.
3. In an initial case, patients who are highly suspicious for primary malignant brain tumor from pre-operative neuro-imaging. In a recurrent case, patient who is diagnosed as primary malignant brain tumor at previous histopathological diagnosis.
1. Patients without surgical tumor removal.
2. Unusable for Talaporfin Sodium.
3. Non intended histopathological types of brain tumor.
4. Patients necessary for VEP monitoring.
5. Pregnancy or possibility of pregnancy.
6. Patients who are expected poor compliance with light shielding protection.
7. Patients regarded as ineligible by principal investigator.
20
1st name | |
Middle name | |
Last name | Kawamata Takakazu |
Tokyo Women's Medical University
The department of neurosurgery
8-1, Kawada-cho, Shinjuku-ku, Tokyo, Japan
03-3353-8111
tkawamata@twmu.ac.jp
1st name | |
Middle name | |
Last name | Chiba Kentaro |
Tokyo Women's Medical University
The department of neurosurgery
8-1, Kawada-cho, Shinjuku-ku, Tokyo, Japan
03-3353-8111
chibak920@gmail.com
Tokyo Women's Medical University
Tokyo Women's Medical University, the department of neurosurgery
Self funding
NO
2018 | Year | 01 | Month | 28 | Day |
Unpublished
Preinitiation
2018 | Year | 01 | Month | 01 | Day |
2018 | Year | 01 | Month | 28 | Day |
2018 | Year | 01 | Month | 18 | Day |
2018 | Year | 01 | Month | 18 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000035260
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |